What was the overall market valuation of the clinical trials market in 2024?

The overall market valuation was $15.84 Billion in 2024. Read More

What is the projected market valuation for the clinical trials market by 2035?

The projected valuation for 2035 is $18.4 Billion. Read More

What is the expected CAGR for the clinical trials market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period 2025 - 2035 is 1.38%. Read More

Which therapeutic area is expected to have the highest valuation in the clinical trials market?

Oncology is expected to have the highest valuation, projected at $6.0 Billion by 2035. Read More

What are the projected valuations for Phase III clinical trials by 2035?

The projected valuation for Phase III clinical trials is $7.2 Billion by 2035. Read More

Which study design segment is anticipated to grow the most in the clinical trials market?

The interventional study design segment is anticipated to grow, with a projected valuation of $7.5 Billion by 2035. Read More

What is the expected valuation for pharmaceutical companies in the clinical trials market by 2035?

The expected valuation for pharmaceutical companies is $7.12 Billion by 2035. Read More

How does the valuation of biotechnology companies compare to that of contract research organizations by 2035?

By 2035, biotechnology companies are expected to reach $5.25 Billion, while contract research organizations may reach $6.03 Billion. Read More

Which key players are leading the clinical trials market?

Key players in the market include Pfizer, Novartis, Roche, Johnson & Johnson, and Merck & Co. Read More

What was the valuation of Phase I clinical trials in 2024?

The valuation of Phase I clinical trials was $2.37 Billion in 2024. Read More

Europe Clinical Trials Market

ID: MRFR/HC/19908-CR

128 Pages

Vikita Thakur

Last Updated: April 10, 2026

Europe Clinical Trials Market Research Report Information By Phase (Phase Trial II, Phase III, Phase IV) , By Study Design (Observational, Interventional, Expanded Access), By Application (Pharmaceutical, Medical Devices, Nutrition, Others) By End Users (Hospitals, Home Care, Ambulatory Surgery Centers) By Service Type( Protocol Designing, Site Identification, Patient Recruitment, Laboratory Services, Bioanalytical Testing Services, Clinical Trial , Data Management Services), By Country (Germany, France, UK, Italy, Spain, Austria, Rest Of Europe, Others) - Forecast Till 2035

Europe Clinical Trials Market Infographic

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Industrial Automation & Equipment, BY Phase (USD Billion) | |
  1. 4.1.1 Phase I | |
  2. 4.1.2 Phase II | |
  3. 4.1.3 Phase III | |
  4. 4.1.4 Phase IV |
2. 4.2 Industrial Automation & Equipment, BY Study Design (USD Billion) | |
  1. 4.2.1 Interventional | |
  2. 4.2.2 Observational | |
  3. 4.2.3 Expanded Access |
3. 4.3 Industrial Automation & Equipment, BY Therapeutic Area (USD Billion) | |
  1. 4.3.1 Oncology | |
  2. 4.3.2 Cardiology | |
  3. 4.3.3 Neurology | |
  4. 4.3.4 Infectious Diseases | |
  5. 4.3.5 Endocrinology |
4. 4.4 Industrial Automation & Equipment, BY End Use (USD Billion) | |
  1. 4.4.1 Pharmaceutical Companies | |
  2. 4.4.2 Biotechnology Companies | |
  3. 4.4.3 Contract Research Organizations 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Pfizer (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Novartis (CH) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Roche (CH) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Johnson & Johnson (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Merck & Co (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 AstraZeneca (GB) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Bristol-Myers Squibb (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 GSK (GB) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Sanofi (FR) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 EUROPE MARKET ANALYSIS BY PHASE |
6. 6.3 EUROPE MARKET ANALYSIS BY STUDY DESIGN |
7. 6.4 EUROPE MARKET ANALYSIS BY THERAPEUTIC AREA |
8. 6.5 EUROPE MARKET ANALYSIS BY END USE |
9. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT |
10. 6.7 RESEARCH PROCESS OF MRFR |
11. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT |
12. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT |
13. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT |
14. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT |
15. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY PHASE, 2024 (% SHARE) |
16. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY PHASE, 2024 TO 2035 (USD Billion) |
17. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY STUDY DESIGN, 2024 (% SHARE) |
18. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY STUDY DESIGN, 2024 TO 2035 (USD Billion) |
19. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY THERAPEUTIC AREA, 2024 (% SHARE) |
20. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion) |
21. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USE, 2024 (% SHARE) |
22. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END USE, 2024 TO 2035 (USD Billion) |
23. 6.20 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
24. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
25. 7.2 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY PHASE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY STUDY DESIGN, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY END USE, 2025-2035 (USD Billion) |
26. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.3.1 |
27. 7.4 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Europe Industrial Automation & Equipment Market Segmentation

Industrial Automation & Equipment By Phase (USD Billion, 2025-2035)

Phase I
Phase II
Phase III
Phase IV

Industrial Automation & Equipment By Study Design (USD Billion, 2025-2035)

Interventional
Observational
Expanded Access

Industrial Automation & Equipment By Therapeutic Area (USD Billion, 2025-2035)

Oncology
Cardiology
Neurology
Infectious Diseases
Endocrinology

Industrial Automation & Equipment By End Use (USD Billion, 2025-2035)

Pharmaceutical Companies
Biotechnology Companies
Contract Research Organizations

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓